Li-Ping Chang

Title: Inventor Spotlight: Li-Ping Chang

Introduction

Li-Ping Chang, based in New Britain, CT, is a prominent inventor known for her groundbreaking contributions to the field of antitumor antibiotics. With a total of three patents to her name, she has made significant strides in developing novel compounds that combat various types of cancer.

Latest Patents

Chang's latest inventions include two noteworthy patents. The first is the production of the novel antitumor antibiotics designated stephacidin A and stephacidin B, which are derived from the fermentation of Actinomadura bacterium ATCC-74432. These antibiotics exhibit promising capabilities in inhibiting the growth of mammalian tumors, particularly prostate carcinoma. The second patent is for an antitumor antibiotic known as BMS-199687, which is obtained by culturing a new strain of Actinomadura ferruginea. This compound has shown antitumor activity in standard animal model systems used for testing.

Career Highlights

Li-Ping Chang is currently affiliated with Bristol-Myers Squibb Company, a leading pharmaceutical company known for its commitment to innovation in the healthcare sector. Her work in developing antitumor antibiotics has contributed significantly to medical science, particularly in the fight against cancer.

Collaborations

Throughout her career, Chang has collaborated with notable colleagues such as Mitsuaki Tsunakawa and Stephen W. Mamber. These collaborations have undoubtedly enhanced her research efforts and fostered innovation in her projects, leading to her successful patents.

Conclusion

Li-Ping Chang's contributions to the field of biotechnology and pharmaceuticals exemplify her dedication to advancing medical treatments. With her innovative work in antitumor antibiotics, she remains a key figure in the ongoing battle against cancer, showcasing the importance of research and patenting in the development of life-saving drugs.